Beta-Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
15 06 2021
Historique:
pubmed: 1 6 2021
medline: 3 11 2021
entrez: 31 5 2021
Statut: ppublish

Résumé

Background Withdrawal of optimal medical therapy has been reported to relapse cardiac dysfunction in patients with dilated cardiomyopathy (DCM) whose cardiac function had improved. However, it is unknown whether beta-blockers can prevent deterioration of cardiac function in those patients. We examined the effect of beta-blockers on left ventricular ejection fraction (LVEF) in recovered DCM. Methods and Results We analyzed the clinical personal record of DCM, a national database of the Japanese Ministry of Health, Labor and Welfare, between 2003 and 2014. Recovered DCM was defined as a previously documented LVEF <40% and a current LVEF ≥40%. Patients with recovered DCM were divided into 2 groups according to the use of beta-blockers. A one-to-one propensity case-matched analysis was used. The primary outcome was defined as a decrease in LVEF >10% at 2 years of follow-up. Of 5370 eligible patients, 4104 received beta-blockers. Propensity score matching yielded 1087 pairs. Mean age was 61.9 years, and 1619 (74.5%) were men. Mean LVEF was 49.3±8.2%, and median B-type natriuretic peptide was 46.6 (interquartile range, 18.0-118.1) pg/mL. The primary outcome was observed less frequently in the beta-blocker group than in the no-beta-blocker group (19.6% versus 24.0%; odds ratio [OR], 0.77; 95% CI, 0.63-0.95;

Identifiants

pubmed: 34053244
doi: 10.1161/JAHA.120.019240
pmc: PMC8477863
doi:

Substances chimiques

Adrenergic beta-Antagonists 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e019240

Subventions

Organisme : Arthritis Research UK
ID : FC001051
Pays : United Kingdom

Références

Lancet. 2019 Jan 5;393(10166):61-73
pubmed: 30429050
J Am Heart Assoc. 2021 Jun 15;10(12):e019240
pubmed: 34053244
Am Heart J. 2012 Jan;163(1):49-56.e2
pubmed: 22172436
J Am Heart Assoc. 2015 Jan 13;4(1):e001504
pubmed: 25587018
J Am Heart Assoc. 2019 Mar 19;8(6):e011077
pubmed: 30845873
JAMA Cardiol. 2016 Aug 1;1(5):510-8
pubmed: 27434402
J Am Coll Cardiol. 2010 Jul 27;56(5):392-406
pubmed: 20650361
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
Stat Methods Med Res. 2019 Jan;28(1):3-19
pubmed: 28573919
Eur J Heart Fail. 2018 Dec;20(12):1735-1743
pubmed: 30255969
Circulation. 1995 Sep 15;92(6):1499-506
pubmed: 7664433
J Am Coll Cardiol. 2002 Mar 20;39(6):946-53
pubmed: 11897434
J Am Coll Cardiol. 2013 Jan 8;61(1):54-63
pubmed: 23287372
Circ J. 2019 Sep 25;83(10):2084-2184
pubmed: 31511439
Br Heart J. 1980 Aug;44(2):134-42
pubmed: 6107091
Can J Cardiol. 2009 May;25(5):e147-50
pubmed: 19417864
Eur Heart J. 2019 Jul 1;40(26):2110-2117
pubmed: 31280320
Circ Cardiovasc Imaging. 2013 Sep;6(5):790-9
pubmed: 23934992
Circ Heart Fail. 2014 May;7(3):434-9
pubmed: 24563449
J Am Coll Cardiol. 2002 Jul 17;40(2):304-10
pubmed: 12106936
Heart. 2011 May;97(9):727-32
pubmed: 21097819
J Card Fail. 2011 Jul;17(7):527-32
pubmed: 21703523
J Am Coll Cardiol. 2012 Dec 18;60(24):2465-72
pubmed: 23158527
J Am Coll Cardiol. 1997 Apr;29(5):1060-6
pubmed: 9120160
Eur J Heart Fail. 2002 Dec;4(6):765-70
pubmed: 12453548
Circulation. 2006 Jan 17;113(2):266-72
pubmed: 16401777
Circulation. 2014 Jun 10;129(23):2380-7
pubmed: 24799515
Circ Heart Fail. 2016 Jul;9(7):
pubmed: 27413037
J Am Coll Cardiol. 1994 Mar 1;23(3):553-9
pubmed: 8113533
Circulation. 2002 Jan 29;105(4):438-45
pubmed: 11815425
Sci Rep. 2018 Jan 31;8(1):1998
pubmed: 29386531
J Am Coll Cardiol. 2011 Mar 29;57(13):1468-76
pubmed: 21435516

Auteurs

Nobuyuki Enzan (N)

Department of Cardiovascular Medicine Faculty of Medical Sciences Kyushu University Fukuoka Japan.

Shouji Matsushima (S)

Department of Cardiovascular Medicine Kyushu University Hospital Fukuoka Japan.

Tomomi Ide (T)

Department of Experimental and Clinical Cardiovascular Medicine Graduate School of Medical Sciences Kyushu University Fukuoka Japan.

Hidetaka Kaku (H)

Department of Cardiology Japan Community Healthcare Organization Kitakyushu Japan.

Takeshi Tohyama (T)

Center for Clinical and Translational Research Kyushu University Hospital Fukuoka Japan.

Kouta Funakoshi (K)

Center for Clinical and Translational Research Kyushu University Hospital Fukuoka Japan.

Taiki Higo (T)

Department of Cardiovascular Medicine Faculty of Medical Sciences Kyushu University Fukuoka Japan.

Hiroyuki Tsutsui (H)

Department of Cardiovascular Medicine Faculty of Medical Sciences Kyushu University Fukuoka Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH